Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

This study has been completed.
Information provided by:
Facet Biotech Identifier:
First received: April 22, 2005
Last updated: August 2, 2008
Last verified: August 2008